Search | Clinical Trials Finder

Conditions: Pediatric Burns
Interventions: Culturelle, Placebo; Dietary Supplement
Lead sponsor: Shriners Hospitals for Children; Other
Eligibility: 6 Months to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Alcohol Dependence
Interventions: ALKS33 (RDC-0313) (1 mg), ALKS33 (RDC-0313) (2.5 mg), ALKS33 (RDC-0313) (10 mg), Placebo; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 27
States / cities: Tucson, Arizona • Cerritos, California • Oceanside, California + 23 more

Conditions: Agitation in Patients With Dementia of the Alzheimer's Type
Interventions: Placebo, AVP-786; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 601 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 93
States / cities: Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 68 more

Conditions: Anaplastic Astrocytoma, Glioblastoma
Interventions: trabedersen, temozolomide, Drug delivery system for administration of AP 12009, Placement of Drug Delivery System, carmustine, lomustine; Drug · Device · Procedure
Lead sponsor: Isarna Therapeutics GmbH; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 3
States / cities: Edison, New Jersey • Mineola, New York • Rochester, New York

Conditions: Healthy
Interventions: AZD7268, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Clostridium Difficile Infection
Interventions: Fecal microbiota transplant G3 capsules, Oral Vancomycin alone; Biological · Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Osteo Arthritis Knee, Pain, Postoperative
Interventions: Tranexamic acid, Placebo; Drug
Lead sponsor: Campbell Clinic; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Germantown, Tennessee

Conditions: Chronic Obstructive Pulmonary Disease, Non-cystic Fibrosis Bronchiectasis
Interventions: Probiotic, Placebo; Dietary Supplement · Other
Lead sponsor: ResBiotic Nutrition, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Miami, Florida • The Villages, Florida

Conditions: Endometriosis Related Pain
Interventions: Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo; Drug
Lead sponsor: Myovant Sciences GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 638 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 43
States / cities: Dothan, Alabama • Mesa, Arizona • Scottsdale, Arizona + 37 more

Conditions: Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
Interventions: SPT-300, Placebo; Drug
Lead sponsor: Seaport Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 29
States / cities: Chino, California • Garden Grove, California • Glendale, California + 25 more

Conditions: NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver, NAFLD - Nonalcoholic Fatty Liver Disease
Interventions: CRV431 75mg, Placebo (1 softgel), CRV431 225mg, Placebo (3 softgels); Drug
Lead sponsor: Hepion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 9
States / cities: Orange, California • Poway, California • Miami, Florida + 5 more

Conditions: Psychosis, Schizophrenia, Schizo Affective Disorder, Schizophreniform
Interventions: Levetiracetam, Placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 16 Years to 35 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Autosomal Dominant Polycystic Kidney, ADPKD
Interventions: Lixivaptan, Placebo; Drug
Lead sponsor: Palladio Biosciences; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 23
States / cities: Hoover, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 20 more

Conditions: Stuttering, Adult
Interventions: Lumateperone (ITI-007), Placebo Tablet or Capsule; Drug
Lead sponsor: CSTrials Inc.; Network
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Costa Mesa, California

Conditions: Androgenetic Alopecia, Androgenic Alopecia, Telogen Effluvium, Thinning Hair, Hair Loss/Baldness, Hair Thinning
Interventions: ALRV5XR, ALRV5XR Shampoo, ALRV5XR Conditioner, ALRV5XR Hair Follicle Serum (Nutriment), Placebo, Placebo Shampoo, Placebo Conditioner, Placebo Hair Follicle Serum (Nutriment); Dietary Supplement · Other
Lead sponsor: Arbor Life Labs; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Irritable Bowel Syndrome With Constipation
Interventions: Linaclotide Dose A, Linaclotide Dose B, Linaclotide Dose C, Linaclotide Approved Adult Dose, Matching Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 46
States / cities: Hot Springs, Arkansas • Little Rock, Arkansas • Anaheim, California + 39 more

Conditions: HIV-1 Infection
Interventions: BMS-986001, Placebo matching with BMS-986001, Efavirenz, Lamivudine, Tenofovir; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 18
States / cities: Sacramento, California • Orlando, Florida • West Palm Beach, Florida + 15 more

Conditions: Radiation Injuries
Interventions: Pendulum Glucose Control (PGC); Biological
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: COVID-19 Pulmonary Complications, COVID-19
Interventions: Zanubrutinib, Supportive Care, Placebo; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 10
States / cities: Fullerton, California • Washington D.C., District of Columbia • Thomasville, Georgia + 6 more

Conditions: COPD
Interventions: Test Product - Tiotropium Bromide Inhalation Powder 18 mcg, Spiriva Handihaler (Tiotropium Bromide) 18 mcg, Placebo; Combination Product
Lead sponsor: Xiromed LLC; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 24
States / cities: Los Angeles, California • Fort Myers, Florida • Gainesville, Florida + 19 more

Conditions: Nasal Congestion
Interventions: Diphenhydramine 50 mg, Diphenhydramine 25 mg, Pseudoephedrine 120 mg; Drug
Lead sponsor: Johnson & Johnson Consumer and Personal Products Worldwide; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 1,021 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 12
States / cities: Austin, Texas • Dallas, Texas • Kerrville, Texas + 4 more

Conditions: Obesity, Vascular Dementia, Cognitive Impairment
Interventions: Urolithin A, Placebo; Dietary Supplement · Other
Lead sponsor: University of Oklahoma; Other
Eligibility: 40 Years to 64 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Disturbed Sleep
Interventions: Ashwagandha, Placebo; Dietary Supplement · Other
Lead sponsor: National University of Natural Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Non Familial Chylocmicronemia Syndrome (Non-FCS)
Interventions: LCQ908, Fenofibrate, Fish Oil, Placebo of LCQ908, Placebo of fenofibrate, Placebo of fish oil; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 28
States / cities: Muscle Shoals, Alabama • Glendale, Arizona • Encinitas, California + 23 more

Search by objective public record fields.

Study of Culturelle in the Prophylaxis of Infection and Diarrhea

ALK33-005: A Study of ALKS33 (RDC-0313) in Adults With Alcohol Dependence

Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma

Phase I Multiple Ascending Dose Study for AZD 7268 in Healthy Volunteers

Fecal Microbiota Transplant for Primary CDI

Extended Oral Tranexamic Acid After Total Knee Arthroplasty

A Study to Evaluate the Effect of Probiotic Supplement on Quality of Life

SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects

Levetiracetam in Early Psychosis

Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease

Lumateperone in the Treatment of Stuttering, Childhood Onset Fluency Disorder

A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Male Subjects With Hair Loss

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation

Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive

Oral 5 Strain Probiotic for GI Toxicity Mitigation During Pelvic Radiation

Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants

Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD)

To Determine if Diphenhydramine Works for Nasal Congestion at Two Different Doses

Urolithin A Supplementation in Middle-aged Adults With Obesity

Ashwagandha for Nighttime Waking

A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia